This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Incyte (INCY) Reports Positive Long-Term Data From HS Study
by Zacks Equity Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
by Zacks Equity Research
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
Incyte (INCY) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
3 Reasons Why Growth Investors Shouldn't Overlook Incyte (INCY)
by Zacks Equity Research
Incyte (INCY) could produce exceptional returns because of its solid growth attributes.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Incyte (INCY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.
LGND vs. INCY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. INCY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Verizon Communications, Honeywell International, CVS Health, Intuit and Incyte
by Zacks Equity Research
Verizon Communications, Honeywell International, CVS Health, Intuit and Incyte are included in this Analyst Blog.
Top Research Reports for Verizon, Honeywell & CVS Health
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks,including Verizon Communications Inc. (VZ), Honeywell International Inc. (HON) and CVS Health Corporation (CVS).
Ligand (LGND) Down 3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Zacks.com featured highlights include e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell
by Zacks Equity Research
e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell are part of the Zacks Screen of the Week article.
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings
by Zacks Equity Research
The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings are part of the Zacks top Analyst Blog.
4 Top-Rated Stocks to Buy Now for Solid Earnings Growth
by Tirthankar Chakraborty
Invest in stocks like e.l.f. Beauty (ELF), Monarch Casino & Resort (MCRI), Incyte (INCY) and Hubbell (HUBB) at the moment for superb earnings growth.
Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Bear Market Rally or Markets Forming a Solid Base: 5 Picks
by Nalak Das
We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.